Associate Professor Jennifer Byrne

Associate Professor
Paediatrics & Child Health, Children's Hospital, Westmead

Telephone +61 2 9845 3027
Fax +61 2 9845 3078

Website Related website

Map

Biographical details

Career Chronology

Jennifer Byrne undertook her PhD with Professor Peter Smith in the University of Queensland's Department of Pathology from 1989-1992. She then spent 3 years in Professor Paul Basset's laboratory in Strasbourg, France as a NH&MRC-funded CJ Martin postdoctoral fellow. She returned to Australia in 1996 to the Children's Medical Research Institute, and then moved to the Children's Cancer Research Unit at The Children's Hospital at Westmead in 1998. She was appointed Acting Head of the Children's Cancer Research Unit in 2008. Research Highlights Since first identifying the tumor protein D52 gene in 1995 (Cancer Res. 55: 2896-903), A/Prof Byrne's work has presented a sequence of original discoveries, including identifying other D52-like genes in human and mouse and thereby a novel gene family (Genomics 35: 523-32), heteromeric interactions between D52-like proteins (Oncogene 16: 873-82), 14-3-3 proteins (J. Mol. Biol. 332: 675-687) and the novel MAL2 protein as partners for D52-like proteins (Genomics 76: 81-88), cell cycle regulation of D52-like protein expression in breast carcinoma cells (Exp. Cell Res. 310: 152-165), and frequent D52 overexpression in breast (Genes Chrom. Cancer 29: 48-57), prostate (Cancer Res. 64: 3814-3822) and ovarian cancer (Int. J. Cancer 117: 1049-1054), in part through gene amplification. A/Prof Byrne has also authored the first reviews of D52-like protein expression and function (Biochem Biophys Res Comm 325: 1115-1121, and references below). Over the last 10 years, her work has been supported by project grants and fellowships of a total value of $1,360,000, including a Cancer Institute NSW Career Development fellowship. Administrative Roles A/Prof Byrne has been a member of the Cancer Biology NHMRC Grant Review Panel in 2006 and 2007, and previously acted as a member of Specialty Committee B (Cell Biology) for the National Ranking of Cancer Research Grants, from 2002-2004. She is now Chair of the CMRI/Children's Hospital at Westmead Institutional Biosafety Committee. A/Prof Byrne is also convenor of the Sydney Branch and Member of the National Executive of the Women in Science Enquiry Network. Postgraduate Teaching Jennifer Byrne is a Conjoint Associate Professor and Deputy Postgraduate Co-ordinator in the Discipline of Paediatrics and Child Health at the University of Sydney. She is also the Faculty of Medicine's conference chair representing for the 2008 From Cell to Society postgraduate student conference. A/Prof Byrne has supervised 4 higher degree students and 5 BSc/ MBBS (Hons) students to completion, and is currently supervising 2 PhD students and 1 BSc (Hons) student. In recognition of her contributions to postgraduate teaching and her own achievements in postgraduate student supervision, she was awarded both the University of Sydney's College of Health Sciences and Faculty of Medicine Awards for Excellence in postgraduate research student supervision for 2005. A/Prof Byrne was previously awarded the University of Sydney Discipline of Paediatrics and Child Health Teaching Award for postgraduate teaching and supervision in 2003.

Research interests

Jennifer Byrne is a molecular biologist based at the Children’s hospital at Westmead in the Oncology Research Unit. She studies the functions of amplification target genes which are overexpressed in multiple cancers, and the clinical significance of target gene overexpression.

Selected grants

2014

  • NanoString nCounter Platform; deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Automated in situ analysis capacity for translational cancer research; Byrne J, Reddel R, Haber M, Norris M, deFazio A; Cancer Institute New South Wales/Equipment Grant.
  • Fluidigm BioMark HD - HX; Alexander I, Jamieson R, Chircop (nee Fabbro) M, Byrne J, Catchpoole D, Reddel R, Tam P, Robinson P, Bryan T, Diefenbach R; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2009

  • Increased tumor protein D52 expression as a marker of breast cancer predispoition, and a possible role in DNA repair; Byrne J; DVC Research/Cancer Research Fund.
  • The molecular basis of cell transformation produced by TPD52 overexpression; Byrne J, Bright R, Smith B, Catchpoole D; Cancer Council New South Wales/Research Project Grants.

2007

  • Flow Cytometry support; Alexander S, Braithwaite A, Bradstock K, Bendall L, Gunning P, Henderson B, Kefford R, Reddel R, Rizos H, Jones C, Byrne J; Cancer Institute New South Wales/Infrastructure Grant.

2005

  • Cancer InstNSW Fell05-Byrne; Byrne J; Cancer Institute New South Wales/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Della-Franca, A., Chen, Y., Byrne, J. (2012). TPD52 (Tumor Protein D52). In Sangdun Choi (Eds.), Encyclopaedia of Signalling Molecules, (pp. 1906-1911). New York: Springer.
  • Weidenhofer, J., Byrne, J. (2009). Isolation of nucleic acids from hard tissues. In Dongyou Liu (Eds.), Handbook of Nucleic Acid Purification, (pp. 427-448). Sydney, Australia: CRC Press.

Journals

  • Shahheydari, H., Frost, S., Smith, B., Groblewski, G., Chen, Y., Byrne, J. (2014). Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Molecular Biology Reports, 41(7), 4565-4572. [More Information]
  • Roslan, N., Bieche, I., Bright, R., Lidereau, R., Chen, Y., Byrne, J. (2014). TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells. Molecular Carcinogenesis, 53(10), 807-819. [More Information]
  • Byrne, J., Frost, S., Chen, Y., Bright, R. (2014). Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumor Biology, 35(8), 7369-7382. [More Information]
  • Bright, J., Schultz, H., Byrne, J., Bright, R. (2013). Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. OncoImmunology, 2(7), 1-11. [More Information]
  • Messenger, S., Thomas, D., Falkowski, M., Byrne, J., Gorelick, F., Groblewski, G. (2013). Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells. American Journal of Physiology: Gastrointestinal and Liver Physiology, 305(6), G439-G452. [More Information]
  • Chen, Y., Kamili, A., Hardy, J., Groblewski, G., Khanna, K., Byrne, J. (2013). Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle, 12(18), 3083-3097. [More Information]
  • Byrne, J., Chen, Y., Martin La Rotta, N., Peters, G. (2012). Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study. Genes and Cancer, 3(2), 87-101. [More Information]
  • Machado, I., Lopez-Guerrero, J., Calabuig-Farinas, S., Hardy, J., Scotlandi, K., Picci, P., Byrne, J., Llombart-Bosch, A. (2011). Clinical significance of tumor protein D52 immunostaining in a large series of Ewing's sarcoma family of tumors. Pediatric and Developmental Pathology, 14(3), 255-256. [More Information]
  • Della-Franca, A., Byrne, J. (2011). TPD52 (tumor protein D52). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 15(06), 483-489. [More Information]
  • Andres-Delgado, L., Anton, O., Madrid, R., Byrne, J., Alonso, M. (2010). Formin INF2 regulates MAL-mediated transport of Lck to the plasma membrane of human T lymphocytes. Blood, 116(26), 5919-5929. [More Information]
  • de Bock, C., Lin, Z., Mekkawy, A., Byrne, J., Wang, Y. (2010). Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International Journal of Oncology, 36(5), 1155-1163. [More Information]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10(497), 1-11. [More Information]
  • Madrid, R., Aranda, J., Rodriguez-Fraticelli, A., Ventimiglia, L., Andres-Delgado, L., Shehata, M., Fanayan, S., Shahheydari, H., Gomez, S., Jimenez, A., Byrne, J., et al (2010). The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. Developmental Cell, 18(5), 814-827. [More Information]
  • Thomas, D., Martin, C., Weng, N., Byrne, J., Groblewski, G. (2010). Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. American Journal of Physiology: Cell Physiology, 298(3), C725-C739. [More Information]
  • Lewis, J., Sullivan, L., Byrne, J., De Riese, W., Bright, R. (2009). Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunology, Immunotherapy: other biological response modifications, 58(8), 1337-1349. [More Information]
  • Fanayan, S., Shehata, M., Agterof, A., McGuckin, M., Alonso, M., Byrne, J. (2009). Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biology, 10, 7-1-7-13. [More Information]
  • Alagaratnam, S., Hardy, J., Lothe, R., Skotheim, R., Byrne, J. (2009). TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Molecular And Cellular Endocrinology, 306(1-2), 75-80. [More Information]
  • Shehata, M., Bie'che, I., Boutros, R., Weidenhofer, J., Fanayan, S., Spalding, L., Zeps, N., Bright, R., Byth Wilson, K., Lidereau, R., Byrne, J. (2008). Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. Clinical Cancer Research, 14(16), 5050-5060. [More Information]
  • Shehata, M., Weidenhofer, J., Thamotharampillai, K., Hardy, J., Byrne, J. (2008). Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Critical Reviews in Oncogenesis, 14(1), 23-44. [More Information]
  • Payton, L., Lewis, J., Byrne, J., Bright, R. (2008). Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunology, Immunotherapy: other biological response modifications, 57(6), 799-811. [More Information]
  • Lewis, J., Payton, L., Whitford, J., Byrne, J., Smith, D., Yang, L., Bright, R. (2007). Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Molecular Cancer Research, 5(2), 133-144.
  • Barbaric, D., Byth Wilson, K., Dalla-Pozza, L., Byrne, J. (2006). Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: Clinical and sample considerations. Leukemia Research: clinical and laboratory studies, 30(11), 1355-1363. [More Information]
  • Boutros, R., Byrne, J. (2005). D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Experimental Cell Research: emphasizing molecular approaches to cell biology, 310(1), 152-165. [More Information]
  • Shehata, M., Boutros, R., Bright, R., Byrne, J. (2005). In vitro models for tumor protein d52 function in cancer cells. Breast Cancer Research, 7(Suppl 2), S37-S37.
  • Tiacci, E., Orvietani, P., Corthals, G., Liso, A., Pileri, S., Byrne, J., Falini, B. (2005). TPD52: A novel B cell/plasma cell protein characterized by unique expression pattern and Ca+2-dependent association with annexin VI. Annals of Oncology, 16(Supplement 5), v78-v78.
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Tiacci, E., Orvietani, P., Bigerna, B., Pucciarini, A., Corthals, G., Pettirossi, V., Martelli, M., Liso, A., Benedetti, R., Byrne, J., et al (2005). Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca 2+-dependent association with annexin VI. Blood, 105(7), 2812-2820. [More Information]
  • Rubin, M., Varambally, S., Beroukhim, R., Tomlins, S., Rhodes, D., Paris, P., Hofer, M., Storz-Schweizer, M., Kuefer, R., et, A., Byrne, J. (2004). Overexpression, Amplification, And Androgen Regulation Of TPD52 In Prostate Cancer. Cancer Research, 64(11), 3814-3822.
  • Boutros, R., Fanayan, S., Shehata, M., Byrne, J. (2004). The Tumor Protein D52 Family: Many Pieces, Many Puzzles. Biochemical and Biophysical Research Communications, 325(4), 1115-1121.
  • Boutros, R., Bailey, A., Wilson, S., Byrne, J. (2003). Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. Journal of Molecular Biology, 332(3), 675-687.
  • Barbaric, D., Dalla-Pozza, L., Byrne, J. (2002). A reliable method of total RNA extraction from frozen human bone marrow samples taken at diagnosis of acute leukaemia. Journal of Clinical Pathology, 55(11), 865-867.
  • de Marco, M., Martin-Belmonte, F., Kremer, L., Albar, J., Correas, I., Vaerman, J., Marazuela, M., Byrne, J., Alonso, M. (2002). MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. The Journal of Cell Biology, 159(1), 37-44.
  • Sum, E., Peng, B., Yu, X., Chen, J., Byrne, J., Lindeman, G., Visvader, J. (2002). The LIM doman protein LM04 interacts with the cofactor CtIP and the tumour suppressor BRCA1 and inhibits BRCA1 activity. Journal of Biological Chemistry, 277(10), 7849-7856.
  • Wilson, S., Bailey, A., Nourse, C., Mattei, M., Byrne, J. (2001). Identification of MAL2, a novel member of the MAL proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics, 76(1-3), 81-88.
  • Sathasivam, P., Bailey, A., Crossley, P., Byrne, J. (2001). The role of the coiled-coil motif in interactions mediated by TPD52. Biochemical and Biophysical Research Communications, 288(1), 56-61.
  • Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes and Cancer, 29(1), 48-57.

2014

  • Shahheydari, H., Frost, S., Smith, B., Groblewski, G., Chen, Y., Byrne, J. (2014). Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Molecular Biology Reports, 41(7), 4565-4572. [More Information]
  • Roslan, N., Bieche, I., Bright, R., Lidereau, R., Chen, Y., Byrne, J. (2014). TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells. Molecular Carcinogenesis, 53(10), 807-819. [More Information]
  • Byrne, J., Frost, S., Chen, Y., Bright, R. (2014). Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumor Biology, 35(8), 7369-7382. [More Information]

2013

  • Bright, J., Schultz, H., Byrne, J., Bright, R. (2013). Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. OncoImmunology, 2(7), 1-11. [More Information]
  • Messenger, S., Thomas, D., Falkowski, M., Byrne, J., Gorelick, F., Groblewski, G. (2013). Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells. American Journal of Physiology: Gastrointestinal and Liver Physiology, 305(6), G439-G452. [More Information]
  • Chen, Y., Kamili, A., Hardy, J., Groblewski, G., Khanna, K., Byrne, J. (2013). Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle, 12(18), 3083-3097. [More Information]

2012

  • Byrne, J., Chen, Y., Martin La Rotta, N., Peters, G. (2012). Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study. Genes and Cancer, 3(2), 87-101. [More Information]
  • Della-Franca, A., Chen, Y., Byrne, J. (2012). TPD52 (Tumor Protein D52). In Sangdun Choi (Eds.), Encyclopaedia of Signalling Molecules, (pp. 1906-1911). New York: Springer.

2011

  • Machado, I., Lopez-Guerrero, J., Calabuig-Farinas, S., Hardy, J., Scotlandi, K., Picci, P., Byrne, J., Llombart-Bosch, A. (2011). Clinical significance of tumor protein D52 immunostaining in a large series of Ewing's sarcoma family of tumors. Pediatric and Developmental Pathology, 14(3), 255-256. [More Information]
  • Della-Franca, A., Byrne, J. (2011). TPD52 (tumor protein D52). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 15(06), 483-489. [More Information]

2010

  • Andres-Delgado, L., Anton, O., Madrid, R., Byrne, J., Alonso, M. (2010). Formin INF2 regulates MAL-mediated transport of Lck to the plasma membrane of human T lymphocytes. Blood, 116(26), 5919-5929. [More Information]
  • de Bock, C., Lin, Z., Mekkawy, A., Byrne, J., Wang, Y. (2010). Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International Journal of Oncology, 36(5), 1155-1163. [More Information]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10(497), 1-11. [More Information]
  • Madrid, R., Aranda, J., Rodriguez-Fraticelli, A., Ventimiglia, L., Andres-Delgado, L., Shehata, M., Fanayan, S., Shahheydari, H., Gomez, S., Jimenez, A., Byrne, J., et al (2010). The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. Developmental Cell, 18(5), 814-827. [More Information]
  • Thomas, D., Martin, C., Weng, N., Byrne, J., Groblewski, G. (2010). Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. American Journal of Physiology: Cell Physiology, 298(3), C725-C739. [More Information]

2009

  • Weidenhofer, J., Byrne, J. (2009). Isolation of nucleic acids from hard tissues. In Dongyou Liu (Eds.), Handbook of Nucleic Acid Purification, (pp. 427-448). Sydney, Australia: CRC Press.
  • Lewis, J., Sullivan, L., Byrne, J., De Riese, W., Bright, R. (2009). Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunology, Immunotherapy: other biological response modifications, 58(8), 1337-1349. [More Information]
  • Fanayan, S., Shehata, M., Agterof, A., McGuckin, M., Alonso, M., Byrne, J. (2009). Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biology, 10, 7-1-7-13. [More Information]
  • Alagaratnam, S., Hardy, J., Lothe, R., Skotheim, R., Byrne, J. (2009). TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Molecular And Cellular Endocrinology, 306(1-2), 75-80. [More Information]

2008

  • Shehata, M., Bie'che, I., Boutros, R., Weidenhofer, J., Fanayan, S., Spalding, L., Zeps, N., Bright, R., Byth Wilson, K., Lidereau, R., Byrne, J. (2008). Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. Clinical Cancer Research, 14(16), 5050-5060. [More Information]
  • Shehata, M., Weidenhofer, J., Thamotharampillai, K., Hardy, J., Byrne, J. (2008). Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Critical Reviews in Oncogenesis, 14(1), 23-44. [More Information]
  • Payton, L., Lewis, J., Byrne, J., Bright, R. (2008). Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunology, Immunotherapy: other biological response modifications, 57(6), 799-811. [More Information]

2007

  • Lewis, J., Payton, L., Whitford, J., Byrne, J., Smith, D., Yang, L., Bright, R. (2007). Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Molecular Cancer Research, 5(2), 133-144.

2006

  • Barbaric, D., Byth Wilson, K., Dalla-Pozza, L., Byrne, J. (2006). Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: Clinical and sample considerations. Leukemia Research: clinical and laboratory studies, 30(11), 1355-1363. [More Information]

2005

  • Boutros, R., Byrne, J. (2005). D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Experimental Cell Research: emphasizing molecular approaches to cell biology, 310(1), 152-165. [More Information]
  • Shehata, M., Boutros, R., Bright, R., Byrne, J. (2005). In vitro models for tumor protein d52 function in cancer cells. Breast Cancer Research, 7(Suppl 2), S37-S37.
  • Tiacci, E., Orvietani, P., Corthals, G., Liso, A., Pileri, S., Byrne, J., Falini, B. (2005). TPD52: A novel B cell/plasma cell protein characterized by unique expression pattern and Ca+2-dependent association with annexin VI. Annals of Oncology, 16(Supplement 5), v78-v78.
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Tiacci, E., Orvietani, P., Bigerna, B., Pucciarini, A., Corthals, G., Pettirossi, V., Martelli, M., Liso, A., Benedetti, R., Byrne, J., et al (2005). Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca 2+-dependent association with annexin VI. Blood, 105(7), 2812-2820. [More Information]

2004

  • Rubin, M., Varambally, S., Beroukhim, R., Tomlins, S., Rhodes, D., Paris, P., Hofer, M., Storz-Schweizer, M., Kuefer, R., et, A., Byrne, J. (2004). Overexpression, Amplification, And Androgen Regulation Of TPD52 In Prostate Cancer. Cancer Research, 64(11), 3814-3822.
  • Boutros, R., Fanayan, S., Shehata, M., Byrne, J. (2004). The Tumor Protein D52 Family: Many Pieces, Many Puzzles. Biochemical and Biophysical Research Communications, 325(4), 1115-1121.

2003

  • Boutros, R., Bailey, A., Wilson, S., Byrne, J. (2003). Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. Journal of Molecular Biology, 332(3), 675-687.

2002

  • Barbaric, D., Dalla-Pozza, L., Byrne, J. (2002). A reliable method of total RNA extraction from frozen human bone marrow samples taken at diagnosis of acute leukaemia. Journal of Clinical Pathology, 55(11), 865-867.
  • de Marco, M., Martin-Belmonte, F., Kremer, L., Albar, J., Correas, I., Vaerman, J., Marazuela, M., Byrne, J., Alonso, M. (2002). MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. The Journal of Cell Biology, 159(1), 37-44.
  • Sum, E., Peng, B., Yu, X., Chen, J., Byrne, J., Lindeman, G., Visvader, J. (2002). The LIM doman protein LM04 interacts with the cofactor CtIP and the tumour suppressor BRCA1 and inhibits BRCA1 activity. Journal of Biological Chemistry, 277(10), 7849-7856.

2001

  • Wilson, S., Bailey, A., Nourse, C., Mattei, M., Byrne, J. (2001). Identification of MAL2, a novel member of the MAL proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics, 76(1-3), 81-88.
  • Sathasivam, P., Bailey, A., Crossley, P., Byrne, J. (2001). The role of the coiled-coil motif in interactions mediated by TPD52. Biochemical and Biophysical Research Communications, 288(1), 56-61.

2000

  • Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes and Cancer, 29(1), 48-57.

To update your profile click here. For support on your academic profile contact .